Skip to content
News
Our CCO recently took part in a wide-ranging discussion on current trends in raw material and API intermediate sourcing. The link to the full article is below:
https://www.pharmtech.com/view/diversifying-the-supply-of-raw-materials
12 July 2024
Following the announcement of the construction of our new “GMP-4” manufacturing facility, the story was featured in a number of industry publications. The below links have more details.
As you know, Google ranks websites partly based on the number of links to that site, so I think adding all of the below will help our search engine ranking.
https://www.pharmoutsourcing.com/1315-News/613867-Navin-Molecular-to-Invest-up-to-35M-to-Expand-GMP-Manufacturing-Capabilities/?catid=6263
https://manufacturingchemist.com/navin-molecular-to-invest-up-to-35-million
https://www.biospectrumindia.com/news/97/24863/navin-molecular-to-invest-35-m-for-expanding-manufacturing-capabilities.html
https://biovoicenews.com/navin-molecular-invests-35-million-to-expand-gmp-manufacturing-capabilities/
https://www.chemanager-online.com/en/news/navin-molecular-plans-eu326-million-expansion-gmp-manufacturing
https://www.echemi.com/cms/1958679.html
https://www.lskh.digital/news/navin-molecular-to-invest-up-to-35-million-to-expand-gmp-manufacturing-capabilities/
https://drug-dev.com/navin-molecular-to-invest-up-to-35-million-to-expand-gmp-manufacturing-capabilities/
https://chemicalweekly.com/news/latestnews/article/632
12 July 2024
Our CCO Jordi Robinson was recently interviewed by Contract Pharma and asked “What are “3 Key Trends” shaping the CDMO industry in 2024 and beyond?”
You can read his thoughts by following the below link. Let us know on our LinkedIn page (https://www.linkedin.com/company/navin-molecular-cdmo) if you agree with Jordi’s thoughts on the future of the CDMO industry.
27 June 2024
Our CCO Jordi Robinson recently sat down with Pharmtech.com as part of their regular “Drug Digest” video series. In a wide-ranging interview, which starts around 27.50, Jordi was asked his opinions on the major changes in the outsourcing landscape in the last few years, including – but not limited – to the current impact the Biosecure act is having on the industry’s attitude to outsourcing.
Access the video here
19 June 2024
Navin Fluorine Board approves Rs 288 Cr (approx. USD 35M) capital investment for the construction of cGMP-4 at our Dewas facility to add additional 200kL multi-purpose capacity.
6 February 2024
